BPL summarise their Ebola precautions
The only organisation in the UK which still makes plasma derived blood products for the treatment of bleeding disorders is Bio Products Laboratory (BPL). BPL has approximately 0.5% of the UK Factor VIII market and 5.2% of the UK Factor IX market.
BPL sources plasma from the USA so once the first Ebola case there had been reported we started receiving enquiries from members asking what precautions are being taken.
We took those concerns straight to the company and have just been sent a summary of BPL procedures prepared by David Wilson (BPL’s Director of Quality). The summary details the the action BPL are taking with regards to safeguarding recipients of their products from the treat from the Ebola virus.
We will continue to monitor the Ebola situation and keep you updated. You can easily keep up to date with all the new information posted on this site by clicking the “follow” button in the bottom right corner of your screen.